DNA tumor vaccines

Archivum Immunologiae et Therapiae Experimentalis

Volumn 49, Issue 1, 2001, Pages 1-11

  Wlazlo, Anthony P ^a   Ertl, Hildegund C J ^a  

^a WISTAR INSTITUTE   (United States)

Author keywords

Cancer; Cytokines; DNA vaccine; Immunity; T cells

Indexed keywords

DNA VACCINE; PLASMID VECTOR; TUMOR VACCINE;

ANTIGEN EXPRESSION; ARTICLE; CANCER CELL; CANCER PREVENTION; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; MAMMAL CELL; NONHUMAN; TARGET CELL;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; HUMANS; NEOPLASMS, EXPERIMENTAL; VACCINES, DNA;

EID: 0035103088     PISSN: 0004069X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (108)

1. AMICI A., VENANZI F. M. and COONCETTI A. (1998): Genetic immunization against neu/erbB2 transgenic breast cancer. Cancer Immunol. Immunother., 47, 183-190.
2. BAROUCH D. H., SANTRA S., STEENBEKE T. D., ZHENG X. X., PERRY H. C., DAVIES M. E., FREED D. C., CRAIU A., STROM T. B., SHIVER J. W. and LETVIN N. L. (1998): Augmentation and suppression of immune responses to an HIV-1 DNA vaccine by plasmid cytokine/Ig administration. J. Immunol., 161, 1875-1882.
3. BIRAGYN A. and KWAK L. W. (1999): B-cell malignancies as a model for cancer vaccines: from prototype protein to next generation genetic fusions. Immunol. Rev., 170, 115-126.
4. BOEL P., WILDMANN C., SENSI M. L., BRASSEUR R., RENAULD J. C., COULIE P., BOON T. and VAN DER BRUGGEN P. (1995): BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. Immunity, 2, 167-175.
5. BOSCH F. X., MANOS M. M., MUNOZ N., SHERMAN M., JANSEN A. M., PPETRO J. SCHIFMAN M. H., MORENO V., KURMAN R. and SHAH K. V. (1995): Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. J. Natl. Cancer Inst., 87, 796-802.
6. BOYLE J. S., BRADY J. L. and LEW A. M. (1998): Enhanced responses to a DNA vaccine encoding a fusion antigen that is directed to sites of immune induction. Nature, 392, 408-411.
7. BRIGHT R. K., BEAMES B., SHEARER M. H. and KENNEDY R. C. (1996): Protection against a lethal tumor challenge with simian virus 40 transformed cells by the direct injection of DNA encoding SV40 large tumor antigen. Cancer Res., 56, 1126-1130.
8. CHACE J. H., HOOKER N. A., MILDENSTEIN K. L., KRIEG A. M. and COWDERY J. S. (1997): Bacterial DNA-induced NK cell IFN-gamma production is dependent on macrophage secretion of IL-12. Clin. Immunol. Immunopathol., 84, 185-193.
9. CHEN S. C., JONES D. H., FYNAN E. F., FARRAR G. H., CLEGG J. C., GREENBERG H. B. and HERRMANN J. E. (1998): Protective immunity induced by oral immunization with a rotavirus DNA vaccine encapsulated in microparticles. J. Virol., 72, 5757-5761.
10. CHEN Y., HU D., ELING D. J., ROBBINS J. and KIPPS T. J. (1998): DNA vaccines encoding full-length or truncated Neu induce protective immunity against Neu-expressing mammary tumors. Cancer Res., 58, 1965-1971.
11. CHEN Y. T., SCANLAN M. J. and SAHIN U. (1997): A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc. Natl. Acad. Sci. USA, 94, 1914-1918.
12. CHOW Y. H., CHIANG B. L., LEE Y. L., CHI W. K., LIN W. C., CHEN Y. T. and TAO M. H. (1998): Development of Th1 and Th2 populations and the nature of immune responses to hepatitis B virus DNA vaccines can be modulated by codelivery of various cytokine genes. J. Immunol., 160, 1320-1329.
13. CHOW Y. H., HUANG W. L., CHI W. K., CHU Y. D. and TAO M. H. (1997): Improvement of hepatitis B virus DNA vaccines by plasmids coexpressing hepatitis B surface antigen and interleukin-2. J. Virol., 71, 169-178.
14. CIERNIK I. F., BERZOFSKY J. A. and CARBONE D. P. (1996): Induction of cytotoxic T lymphocytes and antitumor immunity with DNA vaccines expressing single T cell epitopes. J. Immunol., 156, 2369-2375.
15. CONCETTI A., AMICI A., PETRELLI C., TIBALDI A., PROVINCIALI M. and VENANZI F. M. (1996): Autoantibody to p185erbB2/neu oncoprotein by vaccination with xenogenic DNA. Cancer Immunol. Immunother., 43, 307-315.
16. CONRY R. M., WHITE S. A., FULTZ P. N., KHAZAELI M. B., STRONG T. V., ALLEN K. O., BARLOW D. L., MOORE S. E., COAN P. N., DAVIS I., CURIEL D. T. and LOBUGLIO A. G. (1998): Polynucleotide immunization of non-human primates against carcinoembryonic antigen. Clin. Cancer Res., 4, 2903-2912.
17. CORR M., LEE D. J., CARSON D. A. and TIGHE H. (1996): Gene vaccination with naked plasmid DNA: mechanism of CTL priming. J. Exp. Med., 184, 1555-1560.
18. COULIE P. G., LEHMANN F., LETHE B., HERMAN J., LURQUIN C., ANDRAWISS M. and BOON T. (1995): A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma. Proc. Natl. Acad. Sci. USA, 92, 7976-7980.
19. COX A. L., SKIPPER J., CHEN Y., HENDERSON R. A., DARROW T. L., SHABANOWITZ J., ENGELHARD V. H., HUNT D. F. and SLINGLUFF C. L. (1994): Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science, 264, 716-719.
20. CREW A. J., CLARK J., FISHER C., GILL S., GRIMER R., CHAND A., SHIPLEY J., GUSTERSON B. A. and COOPER C. S. (1995): Fusion of SYT to two genes, SSX1 and SSX2, encoding proteins with homology to the Kruppel-associated box in human synovial sarcoma. EMBO J., 14, 2333-2340.
21. DAVIS H. L., MICHEL M. L. and WHALEN R. G. (1993): DNA-based immunization induces continuous secretion of hepatitis-B surface-antigen and high-levels of circulating antibody. Hum. Mol. Genet., 2, 1847-1851.
22. DIEBOLD S. S., KURSA M., WAGNER E., COTTEN M. and ZENKE M. (1999): Mannose polyethylenimine conjugates for targeted DNA delivery into dendritic cells. J. Biol. Chem., 274, 19087-19094.
23. DISIS M., CALENOFF E., MCLAUGHLIN G., MURPHY A. E., CHEN W., GRONER B., JESCHKE M., LYDON N., MCGLYNN E., LIVINGSTON R. B., MOE R. and CHEEVER M. A. (1994): Existent T cell and antibody immunity to Her-2/neu protein in patients with breast cancer. Cancer Res., 54, 16-20.
24. DOOLAN D. L., SEDEGAH M., HEDSTROM R. C., HOBART P., CHAROENVIT Y. and HOFFMAN S. L. (1996): Circumventing genetic restriction of protection against malaria with multigene DNA immunization: CD8+ T cell-, interferon gamma-, and nitric oxide-dependent immunity. J. Exp. Med., 183, 1739-1746.
25. DYALL R., BOWNE W. B., WEBER L. W., LEMAOULT J., SZABO P., MOROI Y., PISKUN G., LEWIS J. J., HOUGHTON A. N. and NIKOLIC-ZUGIC J. (1998): Heteroclitic immunization induces tumor immunity. J. Exp. Med., 188, 1553-1561.
26. EPSTAIN M., ACHONG B. and BARR Y. (1964): Virus particles in cultured lymphoblasts from Burkitt's lymphoma. Lancet, 1, 702-703.
27. FU T. M., GUAN L., FRIEDMAN A., ULMER J. B., LIU M. A. and DONNELLY J. J. (1998): Induction of MHC class 1-restricted CTL response by DNA immunization with ubiquitin-influenza virus nucleoprotein fusion antigens. Vaccine, 16, 1711-1717.
28. GARIDO F., CABRERA T., CONCHA A., GLEW S., RUIZ-CABELLO F. and STERN P. L. (1993): Natural history of HLA expression during tumor development. Immunol. Today, 14, 491-499.
29. GAUGLER B., VAN DEN EYNDE B., VAN DER BRUGGEN P., ROMERO P., GAFORIO J. J., DE PLAEN E., LETHE B., BRASSUER F. and BOON T. (1994): Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J. Exp. Med., 179, 921-930.
30. GEISSLER M., WANDS G., GESIEN A., DE LA MONTE S., BELLET D. and WANDS J. R. (1997): Genetic immunization with the free human chorionic gonadotropin beta subunit elicits cytotoxic T lymphocyte responses and protects against tumor formation in mice. Lab. Invest., 76, 859-871.
31. GREGORIADIS G., SAFFIE R. and DESOUZA J. B. (1997): Liposome mediated DNA vaccination. FEBS Lett., 402, 107-110.
32. GUEGUEN M., PATARD J. J., GAUGLER B., BRASSEUR F., RENAULD J. C., VAN CANGH P. J., BOON T. and VAN DEN EYNDE B. J. (1998): An antigen recognized by autologous CTLs on a human bladder carcinoma. J. Immunol., 160, 6188-6194.
33. HAN R., CLADEL N. M., REED C. A., PENG X. and CHRISTENSEN N. D. (1999): Protection of rabbits from viral challenge by gene gun-based intracutaneous vaccination with a combination of cottontail rabbit papillomavirus El, E2, E6 and E7 genes. J. Virol., 73, 7039-7043.
34. HAWKINS R. E., WINTER G., HAMBLIN T. J., STEVENSON F. K. and RUSSELL S. J. (1993): A genetic approach to idiotypic vaccination. J. Immunother., 14, 273-278.
35. HEIKE M., WEINMANN A., BETHKE K. and GALLE P. R. (1999): Stress protein/peptide complexes derived from autologous tumor tissue as tumor vaccines. Biochem. Pharmacol., 58, 1381-1387.
36. HOUGHTON A. N. (1994): Cancer antigens: immune recognition of self and altered self. J. Exp. Med., 180, 1-4.
37. HURPIN C., ROTARIOA C., BISCEGLIA H., CHEVALIER M., TARTAGLIA J. and ERDILE L. (1998): The mode of presentation and route of administration are critical for the induction of immune response to p53 and antitumor immunity. Vaccine, 16, 208-215.
38. ISHII N., FUKUSHIMA J., KANEKO T., OKADA E., TANI K., TANAKA S. I., HAMAJIMA K., XIN K. Q., KAWAMOTO S., KOFF W., NISHIOKA K., YASUDA T. and OKUDA K. (1997): Cationic liposomes are a strong adjuvant for a DNA vaccine of HIV-1. AIDS Res. Hum. Retroviruses, 13, 1421-1428.
39. IWASAKI A. and BARBER B. H. (1998): Induction by DNA immunization of a protective antitumor cytotoxic T lymphocyte response against a minimal-epitope-expressing tumor. Cancer Immunol. Immunother., 45, 273-279.
40. JOSEPH B., EKEDAHL J., SIRZEN F., LEWENSOHN R. and ZHIVOTOVSKY B. (1999): Differences in expression of pro-caspases in small cell and non-small cell lung carcinoma. Biochem. Biophys. Res. Commun., 262, 381-387.
41. KAWAKAMI Y., ELIYAHU S., DELGADO C. H., ROBBINS P. F., RIVOLTINI L., TOPALIAN S. L., MIKI T. and ROSENBERG S. A. (1994): Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc. Natl. Acad. Sci. USA, 91, 3515-3519.
42. KIM J. J., BAGARAZZI M. L., TRIVEDI N., HU Y., KAZAHAYA K., WILSON D. M., CICCARELLI R., CHATTERGOON M. A., DANG K., MAHALINGAM S., CHALIAN A. A., AGADJANYAN M. G., BOYER J. D., WANG B. and WEINER D. B. (1997): Engineering of in vivo immune responses to DNA immunization via codelivery of costimulatory molecule genes. Nat. Biotechnol., 15, 641-646.
43. KIM J. J., TRIVEDI N. N., NOTTINGHAM L. K., MORRISON L., TSAI A., HU Y., MAHALINGAM S., DANG K., AHN L., DOYLE N. K., WILSON D. M., CHATTERGOON M. A., CHALIAN A. A., BOYER J. D., AGADJANYAN M. G. and WEINER D. B. (1998): Modulation of amplitude and direction of in vivo immune responses by co-administration of cytokine gene expression cassettes with DNA immunogens. Eur. J. Immunol., 28, 1089-1093.
44. KIM J. J., TRIVEDI N. N., WILSON D. M., MAHALINGAM S., MORRISON L., TSAI A., CHATTERGOON M. A., DANG K., PATEL M., AHN L., BUYER J. D., CHALIAN A. A., KIEBER-EMMONS T., AGADJANYAN M. A., WEINER D. B. and SCHOEMAKER H. (1998): Molecular and immunological analysis of genetic prostate specific antigen (PSA) vaccine (published erratum appears in Oncogene 1999, 18, 2411). Oncogene, 17, 3125-3135.
45. KITTLESEN D. J., THOMPSON L. W. and GULDEN P. H. (1998): Human melanoma patients recognize an HLA-A1-restricted CTL epitope from tyrosinase containing two cysteine residues: implication for tumor vaccine development. J. Immunol., 160, 2099-2106.
46. KLINMAN D. M., YI A. K., BEAUCAGE S. L., CONOVER J. and KRIEG A. M. (1996): CpG motifs present in bacterial DNA rapidly induce lymphocytes to secrete IL-6, 12 and interferon-gamma. Proc. Natl. Acad. Sci. USA, 93, 2879-2883.
47. KOWALCZYK D. and ERTL H. C. J. (1999): Immune responses to DNA vaccines. Cell. Mol. Life Sci., 55, 751-770.
48. KUHOBER A., PUDOLLEK H. P., REIFENBERG K., CHISARI F. V., SCHLICHT H. J., REIMANN J. and SCHIRMBECK R. (1996): DNA immunization induces antibody and cytotoxic T cell responses to hepatitis B core antigen in H-2b mice. J. Immunol., 156, 3687-3695.
49. LANZAVECCHIA A. (1994): How can cryptic epitopes trigger autoimmunity? J. Exp. Med., 181, 1945-1948.
50. LAYLOR R., PORAKISHVILI N., DE SOUZA J. B., PLAYFAIR J. H., DELVES P. J. and LUND T. (1999): DNA vaccination favours memory rather than effector B cell responses. Clin. Exp. Immunol., 117, 106-112.
51. LEHMANN F., MARCHAND M. and HAINAUT P. (1995): Differences in the antigens recognized by cytolytic T cells on two successive metastases of a melanoma patient are consistent with immune selection. Eur. J. Immunol., 25, 340-347.
52. LIN K. Y., GUARNIERI F., STAVELEY-O'CARROLL K. F., LEVITSKY H. I., AUGUST J. T., PARDOLL D. M. and WU T. C. (1996): Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res., 56, 21-26.
53. MARRACK P. and KAPPLER J. (1994): Subversion of the immune system by pathogens. Cell, 76, 323-332.
54. MATSUDA M., SALAZAR F., PETTERSSON M., MASUCCI G., HANSSON J., PISA P., ZHANG Q.-J., MASUCCI M. G. and KIESSLING R. (1993): Interleukin-10 pretreatment protects target cells from, tumor and allospecific cytotoxic T cells and downregulates HLA class I expression. J. Exp. Med., 180, 2371-2375.
55. MENDOZA R. B., CANTWELL M. J. and KIPPS T. J. (1997): Immunostimulatory effects of a plasmid expressing CD40 ligand (CD154) on gene immunization. J. Immunol., 159, 5777-5781.
56. MILAN G., ROSATO A., ZAMBON A., ZANOVELLO P. and COLLAVO D. (1998): DNA immunization in mice against virus-induced tumor antigens. Adv. Exp. Med. Biol., 451, 311-314.
57. MOMMERS E. C., LEONHART A. M., VON MENSDORFF-POUILLY S., SCHOL D. J., HILGERS J., MEIJER C. J., BAAK J. P. and VAN DIEST P. J. (1999): Aberrant expression of MUC1 mucin in ductal hyperplasia and ductal carcinoma in situ of the breast. Int. J. Cancer, 84, 466-469.
58. MONTGOMERY D. L., SHIVER J. W., LEANDER K. R., PERRY H. C., FRIEDMAN A., MARTINEZ D., ULMER J. B., DONNELLY J. J. and LIU M. A. (1993): Heterologous and homologous protection against influenza A by DNA vaccination: optimization of DNA vectors. DNA Cell Biol., 12, 777-783.
59. NAWRATH M., PAVLOVIC J., DUMMET R., SCHULTZ J., STRACK B., HEINRICH J. and MOELLING K. (1999): Reduced melanoma tumor formation in mice immunized with DNA expressing the melanoma-specific antigen gp100/pme117. Leukemia, 1, S48-51.
60. OHWADA A., NAGAOKA I., TAKAHASHI F., TOMINAGA S. and FUKUCHI Y. (1999): DNA vaccination against HuD antigen elicits antitumor activity in a small-cell lung cancer murine model. Am. J. Respir. Cell Mol. Biol., 21, 37-43.
61. OKUDA K., XIN K. O., TSUJI T., BUKAWA H., TANAKA S., KOFF W. C., TANI K., OKUDA K., HONMA K., KAWAMOTO S., HAMAJIMA K. and FUKUSHIMA J. (1997): DNA vaccination followed by macromolecular multicomponent peptide vaccination against HIV-1 induces strong antigen-specific immunity. Vaccine, 15, 1049-1056.
62. OSTRAND-ROSENBERG S., PULASKI B. A., CLEMENTS V. K., QI L., PIPELING M. R. and HANYOK L. A. (1999): Cell-based vaccines for the stimulation of immunity to metastatic cancers. Immunol. Rev., 170, 101-114.
63. + T cell responses in antitumor immunity. Curr. Opin. Immunol., 10, 588-594.
64. PASQUINI S., DENG H., GILES-DAVIS W. and ERTL H. C. J. (1999): The effect of CpG sequences on the B cell response to a viral glycoprotein encoded by a plasmid vector. Gene Ther., 6, 1448-1455.
65. PASS H. I., KENNEDY R. C. and CARBONE M. (1996): Evidence for and implications of SV40-like sequences in human mesotheliomas. Important Adv. Oncol., 89-108.
66. POCZATEK R. B., MYERS R. B., MANNE U., OELSCHLAGER D. K., WEISS H. L., BOSTWICK D. G. and GRIZZLE W. E. (1999): Ep-Cam levels in prostatic adenocarcinoma and prostatic intraepithelial neoplasia. J. Urol., 162, 1462-1466.
67. PROGADOR A., IRVINE K. R., IWASAKI A., BARBER B. H., RESTIFO N. R. and GERMAIN R. N. (1998): Predominant role for directly transfected dendritic cells in antigen presentation to CD8+ T cells after gene gun immunization. J. Exp. Med., 188, 1075-1082.
68. PROGADOR A., SNYDER D. and GILBOA E. (1996): Induction of antitumor immunity using bone marrow-generated dendritic cells. J. Immunol., 156, 2918-2926.
69. RAMSAY A. J., LEONG K. H. and RAMSHAW I. A. (1997): DNA vaccination against virus infection and enhancement of antiviral immunity following consecutive immunization with DNA and viral vectors. Immunol. Cell Biol., 75, 382-388.
70. ROBBINS P. F., EL-GAMIL M., Li Y., TOPALIAN S. L., RIVOLTINI L., SAKAGUCHI K., APPELA E., KAWAKAMI Y. and ROSENBERG S. A. (1995): Cloning of a new gene encoding an antigen recognized by melanoma-specific HLA-A24-restricted tumor-infiltrating lymphocytes. J. Immunol., 154, 5944-5950.
71. RODRIGUEZ F., ZHANG J. and WHITTON J. L. (1997): DNA immunization: ubiquitination of a viral protein enhances cytotoxic T-lymphocyte induction and antiviral protection but abrogates antibody induction. J. Virol., 71, 8497-8503.
72. ROSS R. M., WEBER L. W., WANG S., PISKUN G., DYALL R., SONG P., TAKECHI Y., NIKOLIC-ZUGIC J., HOUGHTON A. N. and LEWIS J. J. (1997): Priming for T-cell-mediated rejection of established tumors by cutaneous DNA immunization. Clin. Cancer Res., 3, 2191-2196.
73. RUBINFELD B., ROBBINS P. and EL-GAMIL M. (1997): Stabilization of beta-catenin by genetic defects in melanoma cell lines. Science, 275, 1790-1792.
74. SASAKI S., TSUJI T., HAMAJIMA K., FUKUSHIMA J., ISHII N., KANEKO T., XIN KQ., MOHRI H., AOKI I., OKUBO T., NISHIOKA K. and OKUDA K. (1997): Monophosphoryl lipid A enhances both humoral and cell-mediated immune responses to DNA vaccination against HIV type 1. Infect. Immun., 65, 3520-3528.
75. SATO Y., ROMAN M., TIGHE H., LEE D., CORR M., NGUYEN M. D., SILVERMAN G. J., LOTZ M., CARSON D. A. and RAZ E. (1996): Immunostimulatory DNA sequences necessary for effective intradermal gene immunization. Science, 273, 352-354.
76. SCHIRMBECK R., BOHM W., ANDO K., CHISARI F. V. and REIMAN J. (1995): Nucleic-acid vaccination primes hepatitis-B virus surface antigen-specific cytotoxic T-lymphocytes in nonresponder mice. J. Virol., 69, 5929-5934.
77. d mice that reject syngeneic tumors. J. Immunol., 157, 3550-3558.
78. SCHNEIDER J., GILBERT S. C., BLANCHARD T. J., HANKE T., ROBSON K. J., HANNAN C. M., BECKER M., SINDEN R., SMITH G. L. and HILL A. V. (1998): Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat. Med., 4, 397-402.
79. SCHRAML P., BENDIK I. and LUDWIG C. U. (1997): Differential messenger RNA and protein expression of the receptor for advanced glycosylated end products in normal lung and non-small cell lung carcinoma. Cancer Res., 57, 3669-3671.
80. SEDEGAH M., JONES T. R., KAUR M., HEDSTROM R., HOBART P., TINE J. A. and HOFFMAN S. L. (1998): Boosting with recombinant vaccinia increases immunogenicity and protective efficacy of malaria DNA vaccine. Proc. Natl. Acad. Sci. USA, 95, 7648-7653.
81. SELIGER B., MAEURER M. J. and FERRONE S. (1997): TAP off tumors on. Immunol. Today, 18, 292-299.
82. SERCARZ E. E., LEHMANN P. V., AMETANI A., BENICHOU G., MILLER A. and MOUDGLI K. (1993): Dominance and cryptivity of T cell antigenic determinants. Annu. Rev. Imrnunol., 11, 729-766.
83. SHICHIJO S., NAKAO M. and IMAI Y. (1998): A gene encoding antigenic peptides of human squamous cell carcinoma recognized by cytotoxic T lymphocytes. J. Exp. Med., 187, 277-288.
84. SMAHEL M., SOBOTKOVA E., VONKA V., HAMSIKOVA E., ZAK R., KITASATO H. and LUDVIKOVA V. (1999): DNA vaccine against oncogenic hamster cells transformed by HPV16 E6/E7 oncogenes and the activated ras oncogene. Oncol. Reports, 6, 211-215.
85. SMANS K. A., INGVARSSON M. B., LINDGREN P., CANEVARI S., WALT H., STIGBRAND T., BACKSTROM T. and MILLAN J. L. (1999): Bispecific antibody-mediated lysis of primary cultures of ovarian carcinoma cells using multiple target antigens. Int. J. Cancer, 83, 270-277.
86. SMITH B. F., BAKER H. J., CURIEL D. T., JIANG W. and CONRY R. M. (1998): Humoral and cellular immune responses of dogs immunized with a nucleic acid vaccine encoding human carcinoembryonic antigen. Gene Ther. 5, 865-868.
87. SYRENGELAS A. D., CHEN T. T. and LEVY R. (1996): DNA immunization induces protective immunity against B cell lymphoma. Nat. Med., 2, 1038-1041.
88. TANG D. C., DEVIT M. and JOHNSTON S. A. (1992): Genetic immunization is a simple method for eliciting an immune response. Nature, 356, 152-154.
89. TAO M.-H and LEVY R. (1993): Idiotype/granulocyte macrophage colony-stimulating factor fusion protein as a vaccine for B cell lymphoma. Nature, 362, 755-761.
90. TORRES C. A. T., IWASAKI A., BARBER B. H. and ROBINSON H. L. (1997): Differential dependence on target site tissue for gene gun and intramuscular DNA immunizations. J. Immunol., 158, 4591-4532.
91. TUTING T., GAMBOTTO A., DELEO A., LOTZE M. T., ROBBINS P. D. and STORKUS W. J. (1999): Induction of tumor antigen-specific immunity using plasmid DNA immunization in mice. Cancer Gene Ther. 6, 73-80.
92. TUTING T., WILSON C. C., MARTIN D. M., BAAR J., DELEO A., LOTZE M. T. and STORKUS W. J. (1998): DNA vaccines targeting dendritic cells for the immunotherapy of cancer. Adv. Exp. Med. Biol., 451, 295-304.
93. TZAHAR E. and YARDEN Y. (1998): The ErbB-2/HER2 oncogenic receptor of adencarcinomas: from orphanhood to multiple stromal ligands. Biochem. Biophys. Acta, 1377, M25-M37.
94. VAN DEN EYNDE B., PEETERS O., DE BACKER O., GAUGLER B., LUCAS S. and BOON T. (1995): A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma. J. Exp. Med., 182, 689-698.
95. VAN DER BRUGGEN P., TRAVERSARI C., CHOMEZ P., LURQUIN C., DEPLAEN E., VAN DEN EYNDE B., KNUTH A. and BOON T. (1991): A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science, 254, 1643-1647.
96. VILE R. G. and HART I. R. (1993): Use of tissue-specific expression of the herpes simplex virus thymidine kinase gene to inhibit growth of established murine melanomas following direct intratumoral injection of DNA. Cancer Res., 53, 3860-3864.
97. VIERBOOM M. P. M., NIJMAN H. W., OFFRINGA R., VAN DER VOORT E. I. H., VAN HALL T., VAN DEN BROEK L., FLEUREN G. J., KENEMANS P., KAST W. M. and MELIEF C. J. M. (1997): Tumor eradication by wild-type p53 specific cytotoxic T lymphocytes. J. Exp. Med., 186, 695-704.
98. WANG R.-F., JOHNSTON S. L., SOUTHWOOD S., SETTE A. and ROSENBERG S. A. (1998): Recognition of an antigenic peptide derived from tyrosinase-related protein-2 by CTL in the context of HLA-A31 and -A33. J. Immunol., 160, 890-897.
99. WANG R.-F., ROBBINS P. F., KAWAKAMI Y., KANG X. Q. and ROSENBERG S. A. (1995): Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor-infiltrating lymphocytes. J Exp. Med., 181, 799-804.
100. WATERMAN J. L., SHENK J. L. and HALAZONETIS T. D. (1995): The dihedral symmetry of the p53 tetramerization domain mandates a conformational switch upon DNA binding. EMBO J., 14, 512-519.
101. WEBER L. W., BOWNE W. B., WOLCHOK J. D., SRINIVASAN R., QIN J., MORCI Y., CLYNES R. SONG P., LEWIS J. J. and HOUGHTON A. N. (1998): Tumor immunity and autoimmunity induced by immunization with homologous DNA. J. Clin. Invest., 102, 1258-1264.
102. WEI W. Z., SHI W. P., GALY A., LICHLYTER D., HERNANDEZ S., GRONER B., HEILBRUN L. and JONES R. F. (1999): Protection against mammary tumor growth by vaccination with full-length, modified human ErbB-2 DNA. Int. J. Cancer, 81, 748-754.
103. WEISS W. R., ISHII K. J., HEDSTROM R. C., SEDEGAH M., ICHINO M., BARNHART K., KLINMAN D. M. and HOFFMAN S. L. (1998): A plasmid encoding murine granulocyte-macrophage colony-stimulating factor increases protection conferred by a malaria DNA vaccine. J. Immunol., 161, 2325-2332.
104. WOLFEL T., HAUER M., SCHNEIDER J., SERRANO M., WOLFEL C., KLEHMANN-HIEB E., DE PLAEN E., HANKELN T., MEYER ZUM BUSCHENFELDE K. H. and BEACH D. (1995): A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science, 269, 1281-1284.
105. XIANG Z. and ERTL H. C. J. (1995): Manipulation of the immune response to a plasmid-encoded viral antigen by coinoculation with plasmids expressing cytokines. Immunity, 2, 129-135.
106. YAMAMOTO S., YAMAMOTO T., SHIMADA S., KURAMOTO E., YANO O., KATAOKA T. and TOKUNAGA T. (1992): DNA from bacteria, but not from vertebrates, induces interferons, activates natural killer cells and inhibits tumor growth. Microbiol. Immunol., 36, 983-997.
107. ZHOU J., LIU W. J., PENG S. W., SUN X. Y. and FRAZER I. (1999): Papillomavirus capsid protein expression level depends on the match between codon usage and tRNA availability. J. Virol., 73, 4972-4982.
108. ZUR HAUSEN H. (1991): Viruses in human cancers. Science, 254, 1167-1173.